Menu
1 min read · estimated
APPROVED USE
What FDA approved
Prevention of cytomegalovirus infection and disease in CMV-seropositive allogeneic hematopoietic stem cell transplant recipients aged 6 months and older and weighing at least 6 kg.
LAMPGEN ANALYSIS
Why it matters
The expansion added an approved prevention option for younger transplant recipients, including those receiving transplants for blood cancers.
What research teams should watch
Capture CMV serostatus, age, weight and cyclosporine use; keep prophylaxis and virologic surveillance timelines aligned.
PRIMARY RECORDS